A phase 1/2a, randomized, placebo-controlled, double-blind, parallel-group, study of safety, tolerability, pharmacokinetics and activity of 14 days of oral dosing with the 2S,4R enantiomer of ketoconazole (DIO-902) in subjects with type 2 diabetes mellitus
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Levoketoconazole (Primary) ; Ketoconazole
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors DiObex
- 07 Oct 2006 New trial record.